1- 磷酸鞘氨醇受体调节剂的研发现状

1- 磷酸鞘氨醇（S1P）具有多种生物学功能，S1P 受体（S1PR）调节剂可以用于治疗多种免疫性疾病。芬戈莫德是首个上市的 S1PR 调节剂，用于治疗多发性硬化症（MS），2015 年销售额达到27 亿美元。药渡网数据显示：目前全球有14 个S1PR 调节剂进入临床， 适应证包括MS、银屑病、类风湿性关节炎和炎症性肠病等。国内目前针对S1PR 靶点的药物有1 个新药奥芬米洛已获批临床，另1 个 新药CBP-307 处于临床在审评阶段。简介S1PR 的生物学功能和S1PR 调节剂在国内外的开发情况，为靶向S1PR 的药物开发提供参考。

Research and Development of Sphingosine 1-Phosphate Modulators

Sphingosine 1-phosphate (S1P) regulates important biological functions, and S1P receptor (S1PR) modulators can be used to treat various autoimmune diseases. Fingolimod was the first approved S1PR modulator by FDA in 2010 for the treatment of multiple sclerosis with 2015 sales amounting to 2.7 billion dollars. Currently, there are 14 S1PR modulators under clinical development, with indications covering MS, psoriasis, rheumatoid arthritis and inflammatory bowel disease. In China, oxfenmino has been approved for clinical trial and another drug CBP-307 is applying for IND. S1PR function and the R&D of S1PR modulators were introduced so as to provide references for the development of S1PRtargeting drugs.